Last reviewed · How we verify
MHB018A injection
MHB018A injection's mechanism is not publicly available.
At a glance
| Generic name | MHB018A injection |
|---|---|
| Sponsor | Minghui Pharmaceutical (Hangzhou) Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Unfortunately, there is limited information available on the exact mechanism of action for MHB018A injection.
Approved indications
Common side effects
Key clinical trials
- Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease (PHASE3)
- MHB018A Treatment in Patients With Chronic Thyroid Eye Disease (PHASE3)
- MHB018A Treatment in Patients With Active Thyroid Eye Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |